nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A5—Dactinomycin—kidney cancer	0.169	0.3	CbGbCtD
Amphetamine—SLC22A3—Vincristine—kidney cancer	0.168	0.298	CbGbCtD
Amphetamine—CYP2D6—Temsirolimus—kidney cancer	0.0841	0.149	CbGbCtD
Amphetamine—CYP2D6—Pazopanib—kidney cancer	0.0442	0.0785	CbGbCtD
Amphetamine—CYP2D6—Erlotinib—kidney cancer	0.0315	0.056	CbGbCtD
Amphetamine—CYP2D6—Sorafenib—kidney cancer	0.0256	0.0455	CbGbCtD
Amphetamine—CYP2D6—Vinblastine—kidney cancer	0.0253	0.045	CbGbCtD
Amphetamine—CYP2D6—Doxorubicin—kidney cancer	0.0156	0.0276	CbGbCtD
Amphetamine—SLC22A5—Temsirolimus—Everolimus—kidney cancer	0.00686	1	CbGdCrCtD
Amphetamine—Pseudoephedrine—IL2—kidney cancer	0.00178	0.25	CrCbGaD
Amphetamine—Ephedrine—ACHE—kidney cancer	0.00139	0.195	CrCbGaD
Amphetamine—Lacosamide—CA9—kidney cancer	0.00104	0.147	CrCbGaD
Amphetamine—Lacosamide—CA2—kidney cancer	0.00094	0.132	CrCbGaD
Amphetamine—Ephedrine—BCHE—kidney cancer	0.000815	0.115	CrCbGaD
Amphetamine—Agitation—Vincristine—kidney cancer	0.000566	0.00178	CcSEcCtD
Amphetamine—Abdominal pain—Vinblastine—kidney cancer	0.000565	0.00177	CcSEcCtD
Amphetamine—Headache—Pazopanib—kidney cancer	0.000565	0.00177	CcSEcCtD
Amphetamine—Body temperature increased—Everolimus—kidney cancer	0.000563	0.00177	CcSEcCtD
Amphetamine—Abdominal pain—Everolimus—kidney cancer	0.000563	0.00177	CcSEcCtD
Amphetamine—Gastrointestinal pain—Erlotinib—kidney cancer	0.000561	0.00176	CcSEcCtD
Amphetamine—Infection—Dactinomycin—kidney cancer	0.000559	0.00176	CcSEcCtD
Amphetamine—Dyspnoea—Sorafenib—kidney cancer	0.000551	0.00173	CcSEcCtD
Amphetamine—Dyspepsia—Sorafenib—kidney cancer	0.000544	0.00171	CcSEcCtD
Amphetamine—Abdominal pain—Erlotinib—kidney cancer	0.000543	0.00171	CcSEcCtD
Amphetamine—Body temperature increased—Erlotinib—kidney cancer	0.000543	0.00171	CcSEcCtD
Amphetamine—Insomnia—Sunitinib—kidney cancer	0.000538	0.00169	CcSEcCtD
Amphetamine—Decreased appetite—Sorafenib—kidney cancer	0.000537	0.00169	CcSEcCtD
Amphetamine—Anorexia—Dactinomycin—kidney cancer	0.000536	0.00168	CcSEcCtD
Amphetamine—Nausea—Pazopanib—kidney cancer	0.000535	0.00168	CcSEcCtD
Amphetamine—Convulsion—Vincristine—kidney cancer	0.000534	0.00168	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000533	0.00168	CcSEcCtD
Amphetamine—Fatigue—Sorafenib—kidney cancer	0.000533	0.00167	CcSEcCtD
Amphetamine—Hypertension—Vincristine—kidney cancer	0.000532	0.00167	CcSEcCtD
Amphetamine—Erythema multiforme—Paclitaxel—kidney cancer	0.000531	0.00167	CcSEcCtD
Amphetamine—Dyspnoea—Sunitinib—kidney cancer	0.00053	0.00166	CcSEcCtD
Amphetamine—Constipation—Sorafenib—kidney cancer	0.000528	0.00166	CcSEcCtD
Amphetamine—Hypersensitivity—Vinblastine—kidney cancer	0.000526	0.00165	CcSEcCtD
Amphetamine—Photosensitivity reaction—Capecitabine—kidney cancer	0.000526	0.00165	CcSEcCtD
Amphetamine—Hypersensitivity—Everolimus—kidney cancer	0.000524	0.00165	CcSEcCtD
Amphetamine—Dyspepsia—Sunitinib—kidney cancer	0.000523	0.00164	CcSEcCtD
Amphetamine—Weight decreased—Capecitabine—kidney cancer	0.000521	0.00164	CcSEcCtD
Amphetamine—Decreased appetite—Sunitinib—kidney cancer	0.000517	0.00162	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000513	0.00161	CcSEcCtD
Amphetamine—Asthenia—Vinblastine—kidney cancer	0.000513	0.00161	CcSEcCtD
Amphetamine—Fatigue—Sunitinib—kidney cancer	0.000512	0.00161	CcSEcCtD
Amphetamine—Depression—Capecitabine—kidney cancer	0.000512	0.00161	CcSEcCtD
Amphetamine—Asthenia—Everolimus—kidney cancer	0.000511	0.0016	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000509	0.0016	CcSEcCtD
Amphetamine—Constipation—Sunitinib—kidney cancer	0.000508	0.0016	CcSEcCtD
Amphetamine—Acute coronary syndrome—Capecitabine—kidney cancer	0.000507	0.00159	CcSEcCtD
Amphetamine—Gastrointestinal pain—Sorafenib—kidney cancer	0.000505	0.00159	CcSEcCtD
Amphetamine—Hypertension—Gemcitabine—kidney cancer	0.000505	0.00158	CcSEcCtD
Amphetamine—Myocardial infarction—Capecitabine—kidney cancer	0.000504	0.00158	CcSEcCtD
Amphetamine—Anaphylactic shock—Vincristine—kidney cancer	0.000503	0.00158	CcSEcCtD
Amphetamine—Infection—Vincristine—kidney cancer	0.000499	0.00157	CcSEcCtD
Amphetamine—Urinary tract infection—Capecitabine—kidney cancer	0.000499	0.00157	CcSEcCtD
Amphetamine—Chest pain—Gemcitabine—kidney cancer	0.000498	0.00156	CcSEcCtD
Amphetamine—Asthenia—Erlotinib—kidney cancer	0.000493	0.00155	CcSEcCtD
Amphetamine—Urticaria—Sorafenib—kidney cancer	0.000491	0.00154	CcSEcCtD
Amphetamine—Decreased appetite—Dactinomycin—kidney cancer	0.000489	0.00154	CcSEcCtD
Amphetamine—Diarrhoea—Vinblastine—kidney cancer	0.000489	0.00154	CcSEcCtD
Amphetamine—Body temperature increased—Sorafenib—kidney cancer	0.000488	0.00153	CcSEcCtD
Amphetamine—Abdominal pain—Sorafenib—kidney cancer	0.000488	0.00153	CcSEcCtD
Amphetamine—Diarrhoea—Everolimus—kidney cancer	0.000487	0.00153	CcSEcCtD
Amphetamine—Gastrointestinal pain—Sunitinib—kidney cancer	0.000486	0.00153	CcSEcCtD
Amphetamine—Hyperhidrosis—Vincristine—kidney cancer	0.000486	0.00153	CcSEcCtD
Amphetamine—Fatigue—Dactinomycin—kidney cancer	0.000485	0.00152	CcSEcCtD
Amphetamine—Tension—Paclitaxel—kidney cancer	0.00048	0.00151	CcSEcCtD
Amphetamine—Anorexia—Vincristine—kidney cancer	0.000479	0.00151	CcSEcCtD
Amphetamine—Anaphylactic shock—Gemcitabine—kidney cancer	0.000477	0.0015	CcSEcCtD
Amphetamine—Nervousness—Paclitaxel—kidney cancer	0.000475	0.00149	CcSEcCtD
Amphetamine—Infection—Gemcitabine—kidney cancer	0.000474	0.00149	CcSEcCtD
Amphetamine—Dizziness—Vinblastine—kidney cancer	0.000472	0.00148	CcSEcCtD
Amphetamine—Dizziness—Everolimus—kidney cancer	0.000471	0.00148	CcSEcCtD
Amphetamine—Abdominal pain—Sunitinib—kidney cancer	0.00047	0.00148	CcSEcCtD
Amphetamine—Body temperature increased—Sunitinib—kidney cancer	0.00047	0.00148	CcSEcCtD
Amphetamine—Diarrhoea—Erlotinib—kidney cancer	0.00047	0.00148	CcSEcCtD
Amphetamine—Benzyl alcohol—CYP1A1—kidney cancer	0.000463	0.0653	CrCbGaD
Amphetamine—Hyperhidrosis—Gemcitabine—kidney cancer	0.000461	0.00145	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.00046	0.00145	CcSEcCtD
Amphetamine—Tremor—Paclitaxel—kidney cancer	0.000458	0.00144	CcSEcCtD
Amphetamine—Hypersensitivity—Sorafenib—kidney cancer	0.000455	0.00143	CcSEcCtD
Amphetamine—Insomnia—Vincristine—kidney cancer	0.000455	0.00143	CcSEcCtD
Amphetamine—Anorexia—Gemcitabine—kidney cancer	0.000455	0.00143	CcSEcCtD
Amphetamine—Vomiting—Vinblastine—kidney cancer	0.000454	0.00143	CcSEcCtD
Amphetamine—Dizziness—Erlotinib—kidney cancer	0.000454	0.00143	CcSEcCtD
Amphetamine—Vomiting—Everolimus—kidney cancer	0.000452	0.00142	CcSEcCtD
Amphetamine—Agitation—Paclitaxel—kidney cancer	0.00045	0.00141	CcSEcCtD
Amphetamine—Rash—Everolimus—kidney cancer	0.000449	0.00141	CcSEcCtD
Amphetamine—Dermatitis—Everolimus—kidney cancer	0.000448	0.00141	CcSEcCtD
Amphetamine—Headache—Vinblastine—kidney cancer	0.000448	0.00141	CcSEcCtD
Amphetamine—Angioedema—Paclitaxel—kidney cancer	0.000447	0.0014	CcSEcCtD
Amphetamine—Headache—Everolimus—kidney cancer	0.000446	0.0014	CcSEcCtD
Amphetamine—Body temperature increased—Dactinomycin—kidney cancer	0.000445	0.0014	CcSEcCtD
Amphetamine—Abdominal pain—Dactinomycin—kidney cancer	0.000445	0.0014	CcSEcCtD
Amphetamine—Asthenia—Sorafenib—kidney cancer	0.000443	0.00139	CcSEcCtD
Amphetamine—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000439	0.00138	CcSEcCtD
Amphetamine—Hypersensitivity—Sunitinib—kidney cancer	0.000438	0.00138	CcSEcCtD
Amphetamine—Decreased appetite—Vincristine—kidney cancer	0.000437	0.00137	CcSEcCtD
Amphetamine—Vomiting—Erlotinib—kidney cancer	0.000437	0.00137	CcSEcCtD
Amphetamine—Erythema multiforme—Capecitabine—kidney cancer	0.000436	0.00137	CcSEcCtD
Amphetamine—Nateglinide—PTGS1—kidney cancer	0.000435	0.0612	CrCbGaD
Amphetamine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000434	0.00136	CcSEcCtD
Amphetamine—Fatigue—Vincristine—kidney cancer	0.000433	0.00136	CcSEcCtD
Amphetamine—Rash—Erlotinib—kidney cancer	0.000433	0.00136	CcSEcCtD
Amphetamine—Dermatitis—Erlotinib—kidney cancer	0.000433	0.00136	CcSEcCtD
Amphetamine—Palpitations—Paclitaxel—kidney cancer	0.000432	0.00136	CcSEcCtD
Amphetamine—Insomnia—Gemcitabine—kidney cancer	0.000431	0.00136	CcSEcCtD
Amphetamine—Headache—Erlotinib—kidney cancer	0.00043	0.00135	CcSEcCtD
Amphetamine—Constipation—Vincristine—kidney cancer	0.00043	0.00135	CcSEcCtD
Amphetamine—Asthenia—Sunitinib—kidney cancer	0.000426	0.00134	CcSEcCtD
Amphetamine—Dyspnoea—Gemcitabine—kidney cancer	0.000425	0.00134	CcSEcCtD
Amphetamine—Nausea—Vinblastine—kidney cancer	0.000424	0.00133	CcSEcCtD
Amphetamine—Somnolence—Gemcitabine—kidney cancer	0.000424	0.00133	CcSEcCtD
Amphetamine—Convulsion—Paclitaxel—kidney cancer	0.000424	0.00133	CcSEcCtD
Amphetamine—Affect lability—Doxorubicin—kidney cancer	0.000423	0.00133	CcSEcCtD
Amphetamine—Nausea—Everolimus—kidney cancer	0.000423	0.00133	CcSEcCtD
Amphetamine—Diarrhoea—Sorafenib—kidney cancer	0.000423	0.00133	CcSEcCtD
Amphetamine—Hypertension—Paclitaxel—kidney cancer	0.000422	0.00133	CcSEcCtD
Amphetamine—Chest pain—Paclitaxel—kidney cancer	0.000417	0.00131	CcSEcCtD
Amphetamine—Anxiety—Paclitaxel—kidney cancer	0.000415	0.0013	CcSEcCtD
Amphetamine—Decreased appetite—Gemcitabine—kidney cancer	0.000415	0.0013	CcSEcCtD
Amphetamine—Hypersensitivity—Dactinomycin—kidney cancer	0.000415	0.0013	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000412	0.00129	CcSEcCtD
Amphetamine—Fatigue—Gemcitabine—kidney cancer	0.000411	0.00129	CcSEcCtD
Amphetamine—Gastrointestinal pain—Vincristine—kidney cancer	0.000411	0.00129	CcSEcCtD
Amphetamine—Dizziness—Sorafenib—kidney cancer	0.000408	0.00128	CcSEcCtD
Amphetamine—Constipation—Gemcitabine—kidney cancer	0.000408	0.00128	CcSEcCtD
Amphetamine—Nausea—Erlotinib—kidney cancer	0.000408	0.00128	CcSEcCtD
Amphetamine—Dry mouth—Paclitaxel—kidney cancer	0.000407	0.00128	CcSEcCtD
Amphetamine—Mood swings—Doxorubicin—kidney cancer	0.000407	0.00128	CcSEcCtD
Amphetamine—Diarrhoea—Sunitinib—kidney cancer	0.000407	0.00128	CcSEcCtD
Amphetamine—Asthenia—Dactinomycin—kidney cancer	0.000404	0.00127	CcSEcCtD
Amphetamine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000399	0.00125	CcSEcCtD
Amphetamine—Abdominal pain—Vincristine—kidney cancer	0.000397	0.00125	CcSEcCtD
Amphetamine—Body temperature increased—Vincristine—kidney cancer	0.000397	0.00125	CcSEcCtD
Amphetamine—Infection—Paclitaxel—kidney cancer	0.000397	0.00125	CcSEcCtD
Amphetamine—Dizziness—Sunitinib—kidney cancer	0.000393	0.00123	CcSEcCtD
Amphetamine—Vomiting—Sorafenib—kidney cancer	0.000393	0.00123	CcSEcCtD
Amphetamine—Abdominal pain upper—Doxorubicin—kidney cancer	0.000393	0.00123	CcSEcCtD
Amphetamine—Tachycardia—Paclitaxel—kidney cancer	0.00039	0.00122	CcSEcCtD
Amphetamine—Rash—Sorafenib—kidney cancer	0.000389	0.00122	CcSEcCtD
Amphetamine—Dermatitis—Sorafenib—kidney cancer	0.000389	0.00122	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000387	0.00122	CcSEcCtD
Amphetamine—Headache—Sorafenib—kidney cancer	0.000387	0.00122	CcSEcCtD
Amphetamine—Hyperhidrosis—Paclitaxel—kidney cancer	0.000386	0.00121	CcSEcCtD
Amphetamine—Diarrhoea—Dactinomycin—kidney cancer	0.000385	0.00121	CcSEcCtD
Amphetamine—Anorexia—Paclitaxel—kidney cancer	0.000381	0.0012	CcSEcCtD
Amphetamine—Vomiting—Sunitinib—kidney cancer	0.000378	0.00119	CcSEcCtD
Amphetamine—Body temperature increased—Gemcitabine—kidney cancer	0.000377	0.00118	CcSEcCtD
Amphetamine—Tremor—Capecitabine—kidney cancer	0.000376	0.00118	CcSEcCtD
Amphetamine—Rash—Sunitinib—kidney cancer	0.000375	0.00118	CcSEcCtD
Amphetamine—Dermatitis—Sunitinib—kidney cancer	0.000374	0.00118	CcSEcCtD
Amphetamine—Headache—Sunitinib—kidney cancer	0.000372	0.00117	CcSEcCtD
Amphetamine—Hypersensitivity—Vincristine—kidney cancer	0.00037	0.00116	CcSEcCtD
Amphetamine—Nausea—Sorafenib—kidney cancer	0.000367	0.00115	CcSEcCtD
Amphetamine—Insomnia—Paclitaxel—kidney cancer	0.000361	0.00113	CcSEcCtD
Amphetamine—Asthenia—Vincristine—kidney cancer	0.000361	0.00113	CcSEcCtD
Amphetamine—Vomiting—Dactinomycin—kidney cancer	0.000358	0.00112	CcSEcCtD
Amphetamine—Dyspnoea—Paclitaxel—kidney cancer	0.000356	0.00112	CcSEcCtD
Amphetamine—Somnolence—Paclitaxel—kidney cancer	0.000355	0.00112	CcSEcCtD
Amphetamine—Palpitations—Capecitabine—kidney cancer	0.000355	0.00111	CcSEcCtD
Amphetamine—Rash—Dactinomycin—kidney cancer	0.000355	0.00111	CcSEcCtD
Amphetamine—Nausea—Sunitinib—kidney cancer	0.000353	0.00111	CcSEcCtD
Amphetamine—Dyspepsia—Paclitaxel—kidney cancer	0.000352	0.0011	CcSEcCtD
Amphetamine—Decreased appetite—Paclitaxel—kidney cancer	0.000347	0.00109	CcSEcCtD
Amphetamine—Hypertension—Capecitabine—kidney cancer	0.000347	0.00109	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000345	0.00108	CcSEcCtD
Amphetamine—Fatigue—Paclitaxel—kidney cancer	0.000344	0.00108	CcSEcCtD
Amphetamine—Diarrhoea—Vincristine—kidney cancer	0.000344	0.00108	CcSEcCtD
Amphetamine—Asthenia—Gemcitabine—kidney cancer	0.000342	0.00107	CcSEcCtD
Amphetamine—Chest pain—Capecitabine—kidney cancer	0.000342	0.00107	CcSEcCtD
Amphetamine—Constipation—Paclitaxel—kidney cancer	0.000341	0.00107	CcSEcCtD
Amphetamine—Anxiety—Capecitabine—kidney cancer	0.000341	0.00107	CcSEcCtD
Amphetamine—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000339	0.00107	CcSEcCtD
Amphetamine—Weight decreased—Doxorubicin—kidney cancer	0.000336	0.00106	CcSEcCtD
Amphetamine—Dry mouth—Capecitabine—kidney cancer	0.000334	0.00105	CcSEcCtD
Amphetamine—Nausea—Dactinomycin—kidney cancer	0.000334	0.00105	CcSEcCtD
Amphetamine—Dizziness—Vincristine—kidney cancer	0.000332	0.00104	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000328	0.00103	CcSEcCtD
Amphetamine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000327	0.00103	CcSEcCtD
Amphetamine—Diarrhoea—Gemcitabine—kidney cancer	0.000326	0.00103	CcSEcCtD
Amphetamine—Infection—Capecitabine—kidney cancer	0.000326	0.00102	CcSEcCtD
Amphetamine—Urinary tract infection—Doxorubicin—kidney cancer	0.000322	0.00101	CcSEcCtD
Amphetamine—Tachycardia—Capecitabine—kidney cancer	0.00032	0.001	CcSEcCtD
Amphetamine—Vomiting—Vincristine—kidney cancer	0.00032	0.001	CcSEcCtD
Amphetamine—Sweating—Doxorubicin—kidney cancer	0.000318	0.000997	CcSEcCtD
Amphetamine—Urticaria—Paclitaxel—kidney cancer	0.000317	0.000997	CcSEcCtD
Amphetamine—Rash—Vincristine—kidney cancer	0.000317	0.000996	CcSEcCtD
Amphetamine—Hyperhidrosis—Capecitabine—kidney cancer	0.000317	0.000995	CcSEcCtD
Amphetamine—Dermatitis—Vincristine—kidney cancer	0.000317	0.000995	CcSEcCtD
Amphetamine—Abdominal pain—Paclitaxel—kidney cancer	0.000316	0.000992	CcSEcCtD
Amphetamine—Body temperature increased—Paclitaxel—kidney cancer	0.000316	0.000992	CcSEcCtD
Amphetamine—Headache—Vincristine—kidney cancer	0.000315	0.000989	CcSEcCtD
Amphetamine—Anorexia—Capecitabine—kidney cancer	0.000312	0.000981	CcSEcCtD
Amphetamine—Vomiting—Gemcitabine—kidney cancer	0.000303	0.000953	CcSEcCtD
Amphetamine—Rash—Gemcitabine—kidney cancer	0.000301	0.000945	CcSEcCtD
Amphetamine—Dermatitis—Gemcitabine—kidney cancer	0.0003	0.000944	CcSEcCtD
Amphetamine—Headache—Gemcitabine—kidney cancer	0.000299	0.000939	CcSEcCtD
Amphetamine—Nausea—Vincristine—kidney cancer	0.000299	0.000938	CcSEcCtD
Amphetamine—Insomnia—Capecitabine—kidney cancer	0.000296	0.000931	CcSEcCtD
Amphetamine—Hypersensitivity—Paclitaxel—kidney cancer	0.000294	0.000924	CcSEcCtD
Amphetamine—Dyspnoea—Capecitabine—kidney cancer	0.000292	0.000918	CcSEcCtD
Amphetamine—Dyspepsia—Capecitabine—kidney cancer	0.000288	0.000906	CcSEcCtD
Amphetamine—Asthenia—Paclitaxel—kidney cancer	0.000287	0.0009	CcSEcCtD
Amphetamine—Decreased appetite—Capecitabine—kidney cancer	0.000285	0.000895	CcSEcCtD
Amphetamine—Nausea—Gemcitabine—kidney cancer	0.000283	0.00089	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000283	0.000889	CcSEcCtD
Amphetamine—Fatigue—Capecitabine—kidney cancer	0.000283	0.000887	CcSEcCtD
Amphetamine—Erythema multiforme—Doxorubicin—kidney cancer	0.000281	0.000883	CcSEcCtD
Amphetamine—Constipation—Capecitabine—kidney cancer	0.00028	0.00088	CcSEcCtD
Amphetamine—Diarrhoea—Paclitaxel—kidney cancer	0.000273	0.000858	CcSEcCtD
Amphetamine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000268	0.000842	CcSEcCtD
Amphetamine—Dizziness—Paclitaxel—kidney cancer	0.000264	0.000829	CcSEcCtD
Amphetamine—Urticaria—Capecitabine—kidney cancer	0.00026	0.000818	CcSEcCtD
Amphetamine—Abdominal pain—Capecitabine—kidney cancer	0.000259	0.000814	CcSEcCtD
Amphetamine—Body temperature increased—Capecitabine—kidney cancer	0.000259	0.000814	CcSEcCtD
Amphetamine—Tension—Doxorubicin—kidney cancer	0.000254	0.000798	CcSEcCtD
Amphetamine—Vomiting—Paclitaxel—kidney cancer	0.000254	0.000798	CcSEcCtD
Amphetamine—Rash—Paclitaxel—kidney cancer	0.000252	0.000791	CcSEcCtD
Amphetamine—Dermatitis—Paclitaxel—kidney cancer	0.000252	0.00079	CcSEcCtD
Amphetamine—Nervousness—Doxorubicin—kidney cancer	0.000251	0.00079	CcSEcCtD
Amphetamine—Headache—Paclitaxel—kidney cancer	0.00025	0.000786	CcSEcCtD
Amphetamine—Hypersensitivity—Capecitabine—kidney cancer	0.000241	0.000758	CcSEcCtD
Amphetamine—Agitation—Doxorubicin—kidney cancer	0.000238	0.000747	CcSEcCtD
Amphetamine—Nausea—Paclitaxel—kidney cancer	0.000237	0.000745	CcSEcCtD
Amphetamine—Selegiline—ABCB1—kidney cancer	0.000236	0.0333	CrCbGaD
Amphetamine—Asthenia—Capecitabine—kidney cancer	0.000235	0.000739	CcSEcCtD
Amphetamine—Palpitations—Doxorubicin—kidney cancer	0.000229	0.000718	CcSEcCtD
Amphetamine—Convulsion—Doxorubicin—kidney cancer	0.000224	0.000704	CcSEcCtD
Amphetamine—Diarrhoea—Capecitabine—kidney cancer	0.000224	0.000704	CcSEcCtD
Amphetamine—Hypertension—Doxorubicin—kidney cancer	0.000223	0.000702	CcSEcCtD
Amphetamine—Chest pain—Doxorubicin—kidney cancer	0.00022	0.000692	CcSEcCtD
Amphetamine—Anxiety—Doxorubicin—kidney cancer	0.00022	0.00069	CcSEcCtD
Amphetamine—Dizziness—Capecitabine—kidney cancer	0.000217	0.000681	CcSEcCtD
Amphetamine—Dry mouth—Doxorubicin—kidney cancer	0.000216	0.000677	CcSEcCtD
Amphetamine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000211	0.000664	CcSEcCtD
Amphetamine—Infection—Doxorubicin—kidney cancer	0.00021	0.000659	CcSEcCtD
Amphetamine—Vomiting—Capecitabine—kidney cancer	0.000208	0.000655	CcSEcCtD
Amphetamine—Rash—Capecitabine—kidney cancer	0.000207	0.000649	CcSEcCtD
Amphetamine—Dermatitis—Capecitabine—kidney cancer	0.000206	0.000648	CcSEcCtD
Amphetamine—Tachycardia—Doxorubicin—kidney cancer	0.000206	0.000648	CcSEcCtD
Amphetamine—Headache—Capecitabine—kidney cancer	0.000205	0.000645	CcSEcCtD
Amphetamine—Hyperhidrosis—Doxorubicin—kidney cancer	0.000204	0.000641	CcSEcCtD
Amphetamine—Anorexia—Doxorubicin—kidney cancer	0.000201	0.000633	CcSEcCtD
Amphetamine—Nausea—Capecitabine—kidney cancer	0.000195	0.000611	CcSEcCtD
Amphetamine—Insomnia—Doxorubicin—kidney cancer	0.000191	0.0006	CcSEcCtD
Amphetamine—Dyspnoea—Doxorubicin—kidney cancer	0.000188	0.000592	CcSEcCtD
Amphetamine—Somnolence—Doxorubicin—kidney cancer	0.000188	0.00059	CcSEcCtD
Amphetamine—Dyspepsia—Doxorubicin—kidney cancer	0.000186	0.000584	CcSEcCtD
Amphetamine—Decreased appetite—Doxorubicin—kidney cancer	0.000184	0.000577	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000182	0.000573	CcSEcCtD
Amphetamine—Fatigue—Doxorubicin—kidney cancer	0.000182	0.000572	CcSEcCtD
Amphetamine—Constipation—Doxorubicin—kidney cancer	0.000181	0.000567	CcSEcCtD
Amphetamine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000173	0.000543	CcSEcCtD
Amphetamine—Urticaria—Doxorubicin—kidney cancer	0.000168	0.000527	CcSEcCtD
Amphetamine—Abdominal pain—Doxorubicin—kidney cancer	0.000167	0.000525	CcSEcCtD
Amphetamine—Body temperature increased—Doxorubicin—kidney cancer	0.000167	0.000525	CcSEcCtD
Amphetamine—Hypersensitivity—Doxorubicin—kidney cancer	0.000156	0.000489	CcSEcCtD
Amphetamine—Asthenia—Doxorubicin—kidney cancer	0.000152	0.000476	CcSEcCtD
Amphetamine—Diarrhoea—Doxorubicin—kidney cancer	0.000145	0.000454	CcSEcCtD
Amphetamine—Dizziness—Doxorubicin—kidney cancer	0.00014	0.000439	CcSEcCtD
Amphetamine—Vomiting—Doxorubicin—kidney cancer	0.000134	0.000422	CcSEcCtD
Amphetamine—Rash—Doxorubicin—kidney cancer	0.000133	0.000418	CcSEcCtD
Amphetamine—Dermatitis—Doxorubicin—kidney cancer	0.000133	0.000418	CcSEcCtD
Amphetamine—Headache—Doxorubicin—kidney cancer	0.000132	0.000416	CcSEcCtD
Amphetamine—Nausea—Doxorubicin—kidney cancer	0.000125	0.000394	CcSEcCtD
Amphetamine—MAOB—Metabolism—CA9—kidney cancer	8.56e-05	0.000818	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—JUNB—kidney cancer	8.55e-05	0.000816	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PAK1—kidney cancer	8.55e-05	0.000816	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PGK1—kidney cancer	8.52e-05	0.000814	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC5A3—kidney cancer	8.52e-05	0.000814	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—kidney cancer	8.46e-05	0.000808	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—kidney cancer	8.45e-05	0.000807	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—kidney cancer	8.35e-05	0.000798	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—LDHB—kidney cancer	8.35e-05	0.000798	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—kidney cancer	8.29e-05	0.000792	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—MAPK1—kidney cancer	7.97e-05	0.000761	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PDHB—kidney cancer	7.94e-05	0.000758	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—POMC—kidney cancer	7.91e-05	0.000756	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—POMC—kidney cancer	7.9e-05	0.000754	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—JUN—kidney cancer	7.9e-05	0.000754	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—PTEN—kidney cancer	7.64e-05	0.000729	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—OR4C13—kidney cancer	7.5e-05	0.000717	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CCBL1—kidney cancer	7.46e-05	0.000713	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	7.46e-05	0.000713	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—ANXA1—kidney cancer	7.32e-05	0.0007	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	7.31e-05	0.000699	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ABCB1—kidney cancer	7.29e-05	0.000696	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CRABP1—kidney cancer	7.28e-05	0.000695	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CA9—kidney cancer	7.24e-05	0.000692	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	7.21e-05	0.000688	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF2—kidney cancer	6.99e-05	0.000668	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN2B—kidney cancer	6.96e-05	0.000665	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—kidney cancer	6.92e-05	0.000661	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTP1—kidney cancer	6.83e-05	0.000653	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ITPR2—kidney cancer	6.77e-05	0.000646	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF1R—kidney cancer	6.76e-05	0.000645	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTP1—kidney cancer	6.74e-05	0.000644	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	6.61e-05	0.000632	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—RAF1—kidney cancer	6.51e-05	0.000622	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GLIPR1—kidney cancer	6.47e-05	0.000618	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPAT—kidney cancer	6.47e-05	0.000618	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—IL2—kidney cancer	6.43e-05	0.000614	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	6.39e-05	0.00061	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LATS1—kidney cancer	6.38e-05	0.00061	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—BRAF—kidney cancer	6.35e-05	0.000607	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTM1—kidney cancer	6.28e-05	0.0006	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTM1—kidney cancer	6.19e-05	0.000591	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ACHE—kidney cancer	6.17e-05	0.000589	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTT1—kidney cancer	6.17e-05	0.000589	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CRABP1—kidney cancer	6.16e-05	0.000588	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—MAPK1—kidney cancer	6.1e-05	0.000583	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APRT—kidney cancer	6.02e-05	0.000575	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—FH—kidney cancer	6.02e-05	0.000575	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP1A1—kidney cancer	5.95e-05	0.000569	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—POMC—kidney cancer	5.93e-05	0.000566	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP1A1—kidney cancer	5.87e-05	0.000561	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SCARB1—kidney cancer	5.84e-05	0.000558	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL2—kidney cancer	5.84e-05	0.000558	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKAP13—kidney cancer	5.81e-05	0.000555	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS1—kidney cancer	5.78e-05	0.000552	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ITPR2—kidney cancer	5.72e-05	0.000547	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—kidney cancer	5.69e-05	0.000544	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PSMD7—kidney cancer	5.67e-05	0.000542	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GPC3—kidney cancer	5.66e-05	0.00054	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HIF1A—kidney cancer	5.56e-05	0.000531	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TSC2—kidney cancer	5.55e-05	0.00053	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CA2—kidney cancer	5.5e-05	0.000526	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AMER1—kidney cancer	5.43e-05	0.000518	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—BCHE—kidney cancer	5.38e-05	0.000513	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALAD—kidney cancer	5.36e-05	0.000512	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KDR—kidney cancer	5.32e-05	0.000508	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SLC5A5—kidney cancer	5.31e-05	0.000507	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—RAF1—kidney cancer	5.3e-05	0.000507	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKAP13—kidney cancer	5.28e-05	0.000504	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ACY1—kidney cancer	5.24e-05	0.0005	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ST3GAL2—kidney cancer	5.23e-05	0.0005	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ACHE—kidney cancer	5.22e-05	0.000499	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTT1—kidney cancer	5.22e-05	0.000499	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—kidney cancer	5.21e-05	0.000498	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SLC2A1—kidney cancer	5.13e-05	0.00049	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALDH1A1—kidney cancer	5.12e-05	0.000489	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	5.04e-05	0.000482	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SCARB1—kidney cancer	4.94e-05	0.000472	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ITPR2—kidney cancer	4.94e-05	0.000472	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PGK1—kidney cancer	4.9e-05	0.000468	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC5A3—kidney cancer	4.9e-05	0.000468	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—APC—kidney cancer	4.9e-05	0.000468	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KIT—kidney cancer	4.9e-05	0.000468	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS1—kidney cancer	4.89e-05	0.000467	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—JUN—kidney cancer	4.83e-05	0.000461	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—LDHB—kidney cancer	4.81e-05	0.000459	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PSMD7—kidney cancer	4.8e-05	0.000458	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—kidney cancer	4.78e-05	0.000457	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—MAPK1—kidney cancer	4.75e-05	0.000454	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	4.71e-05	0.00045	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—MAPK3—kidney cancer	4.69e-05	0.000448	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PTEN—kidney cancer	4.67e-05	0.000446	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—POMC—kidney cancer	4.66e-05	0.000446	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—BRAF—kidney cancer	4.61e-05	0.00044	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—BCHE—kidney cancer	4.55e-05	0.000434	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GPC3—kidney cancer	4.55e-05	0.000434	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CER1—kidney cancer	4.55e-05	0.000434	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC5A5—kidney cancer	4.49e-05	0.000429	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ITPR2—kidney cancer	4.49e-05	0.000428	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—MAPK1—kidney cancer	4.47e-05	0.000427	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PDHB—kidney cancer	4.45e-05	0.000425	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—POMC—kidney cancer	4.44e-05	0.000424	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC2A1—kidney cancer	4.34e-05	0.000414	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTP1—kidney cancer	4.28e-05	0.000409	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—PIK3CA—kidney cancer	4.27e-05	0.000408	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—KRAS—kidney cancer	4.22e-05	0.000403	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CCBL1—kidney cancer	4.19e-05	0.0004	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CA9—kidney cancer	4.17e-05	0.000398	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ANXA1—kidney cancer	4.14e-05	0.000395	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—RAF1—kidney cancer	4.14e-05	0.000395	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—RAF1—kidney cancer	4.12e-05	0.000394	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ABCB1—kidney cancer	4.05e-05	0.000387	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTM1—kidney cancer	3.93e-05	0.000375	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PIK3CA—kidney cancer	3.87e-05	0.00037	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SFRP2—kidney cancer	3.87e-05	0.000369	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RAF1—kidney cancer	3.85e-05	0.000367	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RELA—kidney cancer	3.83e-05	0.000366	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ERBB2—kidney cancer	3.81e-05	0.000363	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ANXA1—kidney cancer	3.76e-05	0.000359	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MTOR—kidney cancer	3.75e-05	0.000359	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP1A1—kidney cancer	3.73e-05	0.000356	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—MAPK1—kidney cancer	3.64e-05	0.000348	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPAT—kidney cancer	3.63e-05	0.000347	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GLIPR1—kidney cancer	3.63e-05	0.000347	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTP1—kidney cancer	3.62e-05	0.000346	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—POMC—kidney cancer	3.59e-05	0.000343	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CRABP1—kidney cancer	3.55e-05	0.000339	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN1B—kidney cancer	3.52e-05	0.000337	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL2—kidney cancer	3.45e-05	0.000329	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ABCB1—kidney cancer	3.43e-05	0.000327	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—FH—kidney cancer	3.37e-05	0.000322	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APRT—kidney cancer	3.37e-05	0.000322	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCND1—kidney cancer	3.36e-05	0.000321	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—JUN—kidney cancer	3.35e-05	0.00032	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CTNNB1—kidney cancer	3.33e-05	0.000318	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTM1—kidney cancer	3.33e-05	0.000318	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ITPR2—kidney cancer	3.3e-05	0.000315	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTEN—kidney cancer	3.24e-05	0.00031	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—kidney cancer	3.22e-05	0.000308	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—kidney cancer	3.19e-05	0.000305	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GPC3—kidney cancer	3.17e-05	0.000303	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP1A1—kidney cancer	3.15e-05	0.000301	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP2—kidney cancer	3.12e-05	0.000298	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKAP13—kidney cancer	3.12e-05	0.000298	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CA2—kidney cancer	3.09e-05	0.000295	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALAD—kidney cancer	3.01e-05	0.000287	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTT1—kidney cancer	3.01e-05	0.000287	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ACHE—kidney cancer	3.01e-05	0.000287	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ST3GAL2—kidney cancer	2.93e-05	0.00028	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—kidney cancer	2.93e-05	0.00028	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALDH1A1—kidney cancer	2.87e-05	0.000274	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—kidney cancer	2.85e-05	0.000272	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRB7—kidney cancer	2.85e-05	0.000272	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SCARB1—kidney cancer	2.85e-05	0.000272	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS1—kidney cancer	2.82e-05	0.000269	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—POMC—kidney cancer	2.78e-05	0.000265	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK3—kidney cancer	2.77e-05	0.000265	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PSMD7—kidney cancer	2.76e-05	0.000264	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PGK1—kidney cancer	2.75e-05	0.000263	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC5A3—kidney cancer	2.75e-05	0.000263	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LDHB—kidney cancer	2.7e-05	0.000258	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MYC—kidney cancer	2.7e-05	0.000258	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ITPR2—kidney cancer	2.65e-05	0.000253	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK1—kidney cancer	2.64e-05	0.000252	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—BCHE—kidney cancer	2.62e-05	0.00025	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC5A5—kidney cancer	2.59e-05	0.000247	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC2A1—kidney cancer	2.5e-05	0.000239	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KRAS—kidney cancer	2.49e-05	0.000238	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CTNNA1—kidney cancer	2.4e-05	0.000229	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EIF4EBP1—kidney cancer	2.39e-05	0.000228	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HSPB1—kidney cancer	2.39e-05	0.000228	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—POMC—kidney cancer	2.35e-05	0.000225	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CA9—kidney cancer	2.34e-05	0.000223	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CA—kidney cancer	2.29e-05	0.000219	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PSMD7—kidney cancer	2.22e-05	0.000212	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TSC1—kidney cancer	2.22e-05	0.000212	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ANXA1—kidney cancer	2.22e-05	0.000212	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—kidney cancer	2.22e-05	0.000212	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—kidney cancer	2.21e-05	0.000212	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FLT1—kidney cancer	2.15e-05	0.000205	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTP1—kidney cancer	2.08e-05	0.000199	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—POMC—kidney cancer	2.03e-05	0.000194	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JUNB—kidney cancer	1.99e-05	0.00019	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PAK1—kidney cancer	1.99e-05	0.00019	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CRABP1—kidney cancer	1.99e-05	0.00019	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCB1—kidney cancer	1.97e-05	0.000188	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTEN—kidney cancer	1.93e-05	0.000185	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTM1—kidney cancer	1.91e-05	0.000183	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—kidney cancer	1.87e-05	0.000179	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ITPR2—kidney cancer	1.85e-05	0.000177	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—POMC—kidney cancer	1.84e-05	0.000176	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP1A1—kidney cancer	1.82e-05	0.000173	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ACHE—kidney cancer	1.69e-05	0.000161	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTT1—kidney cancer	1.69e-05	0.000161	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTEN—kidney cancer	1.63e-05	0.000156	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF2—kidney cancer	1.63e-05	0.000156	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN2B—kidney cancer	1.62e-05	0.000155	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SCARB1—kidney cancer	1.6e-05	0.000152	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS1—kidney cancer	1.58e-05	0.000151	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1R—kidney cancer	1.58e-05	0.000151	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PSMD7—kidney cancer	1.55e-05	0.000148	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—RAF1—kidney cancer	1.52e-05	0.000145	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2—kidney cancer	1.5e-05	0.000143	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—BCHE—kidney cancer	1.47e-05	0.00014	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.45e-05	0.000139	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.4e-05	0.000134	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CA—kidney cancer	1.36e-05	0.00013	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2—kidney cancer	1.36e-05	0.00013	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—POMC—kidney cancer	1.35e-05	0.000129	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HIF1A—kidney cancer	1.3e-05	0.000124	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TSC2—kidney cancer	1.29e-05	0.000124	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KDR—kidney cancer	1.24e-05	0.000119	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTP1—kidney cancer	1.17e-05	0.000112	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CA—kidney cancer	1.15e-05	0.00011	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APC—kidney cancer	1.14e-05	0.000109	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KIT—kidney cancer	1.14e-05	0.000109	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCB1—kidney cancer	1.11e-05	0.000106	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAPK3—kidney cancer	1.09e-05	0.000105	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—POMC—kidney cancer	1.09e-05	0.000104	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—kidney cancer	1.08e-05	0.000103	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BRAF—kidney cancer	1.07e-05	0.000103	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM1—kidney cancer	1.07e-05	0.000103	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAPK1—kidney cancer	1.04e-05	9.95e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP1A1—kidney cancer	1.02e-05	9.72e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	9.95e-06	9.51e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KRAS—kidney cancer	9.84e-06	9.4e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTEN—kidney cancer	9.41e-06	8.99e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	9.04e-06	8.63e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RAF1—kidney cancer	8.97e-06	8.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RELA—kidney cancer	8.93e-06	8.53e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB2—kidney cancer	8.87e-06	8.48e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MTOR—kidney cancer	8.76e-06	8.36e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1B—kidney cancer	8.22e-06	7.85e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2—kidney cancer	8.04e-06	7.68e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCND1—kidney cancer	7.84e-06	7.49e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JUN—kidney cancer	7.82e-06	7.47e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CTNNB1—kidney cancer	7.76e-06	7.42e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—POMC—kidney cancer	7.59e-06	7.25e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTEN—kidney cancer	7.57e-06	7.23e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—kidney cancer	6.83e-06	6.53e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CA—kidney cancer	6.64e-06	6.34e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK3—kidney cancer	6.47e-06	6.18e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MYC—kidney cancer	6.29e-06	6.01e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK1—kidney cancer	6.15e-06	5.88e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—kidney cancer	6.05e-06	5.78e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KRAS—kidney cancer	5.81e-06	5.55e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CA—kidney cancer	5.34e-06	5.1e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTEN—kidney cancer	5.28e-06	5.04e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—kidney cancer	5.16e-06	4.93e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CA—kidney cancer	3.72e-06	3.56e-05	CbGpPWpGaD
